淀粉样蛋白PET定量用于未来临床实践:最新进展综述
本综述总结了淀粉样蛋白PET定量的可用工具与指标。视觉二分法忽略Aβ沉积的连续性,定量方法可生成不依赖示踪剂的Aβ负荷测量,在AD连续谱最早阶段显示病理改变并生成更敏感阈值,提高诊断信心;大型多中心研究显示淀粉样蛋白PET结果改变诊断与患者管理,定量可准确预测认知下降速率,但是否改善临床结局尚未确定,需进一步验证。
要点
- 视觉二分法将扫描判为Aβ阳性或阴性,但灰质示踪剂沉积随淀粉样负荷变化是连续过程。
- 定量方法可生成不依赖示踪剂的Aβ负荷测量,在AD连续谱最早阶段显示病理改变并生成更敏感阈值。
- 大型多中心研究显示淀粉样蛋白PET结果改变诊断与患者管理,定量可准确预测认知下降速率。
核心结论
- 淀粉样蛋白PET定量方法在临床与研究中的应用正在增长,但管理改变是否反映临床结局改善尚未确定,需进一步验证以确立定量对支持治疗终点决策的效用。
研究设计与样本
- 本综述为最新进展综述,总结了淀粉样蛋白PET定量的多种可用工具与指标。
主要发现
- 视觉判读将扫描分为Aβ阳性或阴性,诊断决策常基于此,临床试验患者选择也日益由淀粉样状态指导。
- 灰质中示踪剂沉积随淀粉样负荷变化本质上是连续过程,仅凭二元截断值不能充分体现。
- 定量方法可生成不依赖示踪剂的Aβ负荷测量,在AD连续谱最早阶段显示病理改变并生成更敏感阈值,提高既定二元截断值附近的诊断信心。
- 大型多中心研究显示淀粉样蛋白PET结果改变诊断与患者管理,定量可准确预测认知下降速率。
关键数值与推荐
- 三种氟-18标记放射性示踪剂已获批临床使用。
临床怎么用
- 临床实践中,受过培训的判读者基于视觉检查将扫描分类为Aβ阳性或阴性。
- 定量淀粉样蛋白测量在临床试验中用于治疗反应监测。
- FDA近期批准阿杜那单抗(aducanumab)且更多候选药物即将出现,使用定量测量早期识别淀粉样负荷对入选合适受试者以确立治疗干预和二级预防的最佳窗口至关重要。
局限性
- 管理改变是否反映临床结局改善尚未确定。
- 需进一步验证工作以确立定量对支持治疗终点决策的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo using positron emission tomography (PET), for which three fluorine-18 labelled radiotracers have been approved for clinical use. In clinical practice, trained readers will categorise scans as either Aβ positive or negative, based on visual inspection. Diagnostic decisions are often based on these reads and patient selection for clinical trials is increasingly guided by amyloid status. However, tracer deposition in the grey matter as a function of amyloid load is an inherently continuous process, which is not sufficiently appreciated through binary cut-offs alone. State-of-the-art methods for amyloid PET quantification can generate tracer-independent measures of Aβ burden. Recent research has shown the ability of these quantitative measures to highlight pathological changes at the earliest stages of the AD continuum and generate more sensitive thresholds, as well as improving diagnostic confidence around established binary cut-offs. With the recent FDA approval of aducanumab and more candidate drugs on the horizon, early identification of amyloid burden using quantitative measures is critical for enrolling appropriate subjects to help establish the optimal window for therapeutic intervention and secondary prevention. In addition, quantitative amyloid measurements are used for treatment response monitoring in clinical trials. In clinical settings, large multi-centre studies have shown that amyloid PET results change both diagnosis and patient management and that quantification can accurately predict rates of cognitive decline. Whether these changes in management reflect an improvement in clinical outcomes is yet to be determined and further validation work is required to establish the utility of quantification for supporting treatment endpoint decisions. In this state-of-the-art review, several tools and measures available for amyloid PET quantification are summarised and discussed. Use of these methods is growing both clinically and in the research domain. Concurrently, there is a duty of care to the wider dementia community to increase visibility and understanding of these methods.
引用
- Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022. PMID: 35389071. doi:10.1007/s00259-022-05784-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。